Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022

Dr. Kellum Invited to Participate on Additional Featured Panels

TORONTO, June 14, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), are pleased to announce that Dr. John Kellum, the Company’s CMO, will be featured as the keynote lecturer at the virtual 40th Vicenza Course on Acute Kidney Injury from Tuesday, June 14, 2022, to Thursday, June 16, 2022.

Dr. Kellum will present the following lectures:

Biomarkers derived AKI definition
Dr. Kellum will discuss new data published in May in JAMA Open describing the role of biomarkers in classification of acute kidney injury on Tuesday, June 14, 2022, at 9:40 AM CET. 

Blood purification in sepsis
Dr. Kellum will give a lecture entitled “Why are we using EBP in sepsis?” where he will discuss the rationale for polymyxin B hemoperfusion and other therapies in sepsis on Wednesday, June 15, 2022, at 10:40 AM CET.

Dr. Kellum has been invited to participate in the following featured panels:

Endotoxemia in the critically ill and the role of Polymyxin B Hemoperfusion 
Dr. Kellum will discuss Endotoxemia and Endotoxic Shock and why we should care on Tuesday, June 14, 2022, at 6:30 AM Eastern Time. 

Time to shift gears with AKI biomarkers
Dr. Kellum will discuss availability of new tools for decision making on Thursday, June 16, 2022, at 7:15 AM Eastern Time.

About Spectral

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Contact: